Exploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS database
There are differences in the types of cardiac adverse events induced by relugolix and degarelix. Clinicians should consider their differences and enhanced electrocardiogram monitoring when prescribing GnRH antagonists to their patients.
Authors
- Jianhui Chen (ORCID: https://orcid.org/0000-0001-7494-1258)
- Bijuan Lin (ORCID: https://orcid.org/0000-0002-8499-8466)
- Meina Lv (ORCID: https://orcid.org/0000-0002-3900-7723)
- Maobai Liu (ORCID: https://orcid.org/0000-0002-8382-7868)
- Bin Zheng
Institutions
- Fujian Medical University (CN)
- Union Hospital (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1080/14740338.2025.2488239
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00